Investors


Introduction


Helix BioPharma's product development initiatives include its novel LDOS47 new drug product candidate for the treatment of inoperable Locally advanced recurrent. For more information contact Investor Realation or Shareholder Services

TSX:HBP

LATEST ANNUAL REPORTQ1 2020 RESULTSCORPORATE PRESNTATION 2019

Latest news

All News
Image

Latest news

All News
Image
Input your text here! The text element is intended for longform copy that could potentially include multiple paragraphs.

Latest news

All News

Latest news

All News

Latest Presentations

All Events

Constating Documents

Artical of Amendment

Helix BioPharma Corp.by-law